|
|
| |
5th
May 2009
Dolphin has added seven more formulations to its growing
Sri Lanka Portfolio
|
|
28th
April 2009
The Board of Directors of the Company in its 154th
meeting held on Tuesday, 28 April, 2009 has recommended 50% cash and 25% stock
dividend (bonus share)
|
|
|
 |
 |
 |
 |
 |
| D- Metronidazole Suspension |
|
| Back |
| DESCRIPTION |
D- Metronidazole is an antimicrobial drugs with high activity against anaerobic bacteria and protozoa; indications include trichomonal vaginitis, bacterial vaginitis, and Entamoeba histolytica and Giardia lamblia infections. It is also used for surgical and gynaecological sepsis in which its activity against colonic anaerobes, especially Bacteroids fragilis, is important. Metronidazole is also effective in the treatment of antibiotic associated colitis (pseudomembranous colitis). D- Metronidazole is readily absorbed following administration by mouth and bioavailability approaches 100%. D- Metronidazole is widely distributed in the body. It appears in most body tissues and fluids.
|
| INDICATIONS |
Anaerobic infections (including dental), protozoal infections, Helicobater pylori eradication and skin infections.
|
| DOSAGE AND ADMINISTRATION |
By mouth.
Indications
|
Duration of
Dose |
Child |
7-10 years |
3-7 years |
1-3 years |
Amoebiasis |
|
|
|
|
a) Amoebic dysentery |
5-10 days or 2 days |
400 mg thrice daily |
200 mg four times daily |
200 mg thrice daily |
b) Asymptomatic amoebic infection |
5-10 days |
200-400 mg thrice daily |
100-200 mg four times daily |
100-200 mg thrice daily |
c) Intestinal disease in less susceptible patients and chronic amoebic hepatitis |
5-10 days or 2 days |
200-400 mg thrice daily |
100-200 mg four times daily |
100-200 mg thrice daily |
d) Extra -intestinal amoebiasis |
5-10 days |
200-400 mg thrice daily |
100-200 mg four times daily |
100-200 mg thrice daily |
e) Symptomless cyst passers |
5-10 days |
200-400 mg thrice daily |
100-200 mg four times daily |
100-200 mg thrice daily |
Giardiasis |
3 days |
1 gm once daily |
700 mg once daily |
500 mg once daily |
Urogenital trichomoniasis |
7 days or 2 days or 1 day |
100 mg thrice daily |
100 mg twice daily |
50 mg thrice daily |
Bacterial vaginitis |
7 days or Single dose |
|
|
|
Acute dental infections |
3-7 days |
100 mg thrice daily |
100 mg twice daily |
50 mg thrice daily |
Severe ulcerative gingivitis |
3 days |
100 mg thrice daily |
100 mg twice daily |
50 mg thrice daily |
Anaerobic infection |
7 days |
7.5 mg/kg thrice daily in divided dose |
|
| CONTRAINDICATION |
Known hypersensitivity to metronidazole.
|
| PRECAUTION |
|
Disulfiram-like reaction with alcohol, hepatic impairment and hepatic encephalopathy; clinical and laboratory monitoring advised if treatment exceeds 10 days.
|
| PREGNANCY AND LACTATION |
There is inadequate evidence of the safety of metronidazole in pregnancy. D- Metronidazole should not, therefore, be given during pregnancy or during lactation unless the physician considers it essential; in these circumstances the short, high-dosage regimens are not recommended.
|
| SIDE EFFECTS |
|
Nausea, vomiting, unpleasant taste, furred tongue, and gastrointestinal disturbances; rashes, urticaria and angioedema; rarely drowsiness, headache, dizziness, ataxia, darkening of urine, and anaphylaxis; on prolonged or intensive therapy peripheral neuropathy, transient epileptiform seizures, and leucopenia.
|
| PHARMACEUTICAL PRECAUTION |
Store in a cool and dry place, away from light. Keep out of reach of children.
|
| PACKAGING |
D- Metronidazole Suspension : Bottle containing 60 ml suspension. Each 5 ml contains metronidazole BP 333 mg.
|
|
|
 |
 |
 |
 |
 |
 |
 |
|
|
